Cochlear Implantation in Patients With CHARGE Syndrome: A Systematic Review and Meta-Analysis.

Otol NeurotolMay 6, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Pediatrics

Kalena Liu, Jacob Beiriger, Eric Fei et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated cochlear implantation (CI) outcomes in 85 patients with CHARGE syndrome across 15 studies. The analysis revealed significant postoperative improvements in auditory outcomes, with an overall pre/post mean difference of 11.9 in IT-MAIS scores (P = 0.036) and 2.9 in CAP scores (P = 0.004), indicating enhanced auditory perception following CI.

Key findings

  • Significant increase in IT-MAIS scores post-CI with a mean difference of 11.9 (P = 0.036).
  • Significant increase in CAP scores post-CI with a mean difference of 2.9 (P = 0.004).
  • The analysis included data from 85 CHARGE patients with 99 implanted ears.

Why it matters

Understanding the outcomes of cochlear implantation in patients with CHARGE syndrome is crucial for clinicians, as it informs treatment decisions and expectations for auditory development in this complex population.

Source

PubMed · PMID 42087294

Published in Otol Neurotol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.